John Oyler Sells 145,861 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 145,861 shares of the firm’s stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the transaction, the chief executive officer owned 8,122 shares in the company, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Trading Up 1.5%

Shares of NASDAQ ONC opened at $311.26 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $385.22. The company has a market cap of $34.15 billion, a price-to-earnings ratio of 69.63 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock’s 50 day simple moving average is $290.20 and its 200 day simple moving average is $308.90.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ONC. Leerink Partners upped their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Royal Bank Of Canada boosted their price objective on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Citizens Jmp reissued a “market outperform” rating and issued a $396.00 price objective on shares of BeOne Medicines in a report on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Barclays cut their target price on BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $390.92.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONC. Bank of America Corp DE acquired a new position in BeOne Medicines in the 2nd quarter valued at approximately $67,657,000. Man Group plc purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $59,031,000. BNP Paribas Financial Markets acquired a new position in shares of BeOne Medicines in the second quarter worth $38,337,000. First Trust Advisors LP raised its holdings in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of BeOne Medicines during the second quarter worth $26,034,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.